Firefly and NeuroSigma partner to expand pediatric ADHD treatment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. S
10. COF

Go back to Firefly and NeuroSigma partner to expand pediatric ADHD treatment

Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

September 25, 2026 7:45 AM EDT

Partnership will introduce NeuroSigmas second-generation Monarch eTNS® System to Fireflys nationwide network of Evoke clinicians

Collaboration brings together an FDA-cleared pediatric ADHD treatment and Fireflys objective brain-function assessment platform and AI-driven ADHD biomarker research

Monarch offers an at-home, non-medication treatment option for eligible children ages 7 through 12

KENMORE, N.Y. and LOS ANGELES, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (Firefly) (NASDAQ: AIFF), an artificial intelligence (AI) company advancing precision neuroscience, and NeuroSigma, Inc. (NeuroSigma), a bioelectronic medical device company,... More